OMERS ADMINISTRATION Corp Has $1.41 Million Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

OMERS ADMINISTRATION Corp lowered its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 21.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 15,700 shares of the medical equipment provider’s stock after selling 4,400 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in Lantheus were worth $1,405,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Kestra Investment Management LLC acquired a new position in shares of Lantheus in the 4th quarter valued at $27,000. Summit Securities Group LLC acquired a new position in shares of Lantheus in the 4th quarter valued at $37,000. UMB Bank n.a. lifted its stake in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 134 shares during the period. Parkside Financial Bank & Trust lifted its stake in shares of Lantheus by 49.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock valued at $76,000 after purchasing an additional 280 shares during the period. Finally, 1620 Investment Advisors Inc. acquired a new position in shares of Lantheus in the 4th quarter valued at $125,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on LNTH. B. Riley cut their price target on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Finally, Truist Financial dropped their price objective on Lantheus from $127.00 to $117.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, Lantheus has an average rating of “Buy” and a consensus price target of $132.67.

Lantheus Trading Up 1.2%

Shares of Lantheus stock opened at $79.78 on Friday. The company has a market capitalization of $5.46 billion, a PE ratio of 13.27 and a beta of 0.23. Lantheus Holdings, Inc. has a 12 month low of $75.00 and a 12 month high of $126.89. The stock’s fifty day simple moving average is $97.57 and its 200 day simple moving average is $93.51.

Lantheus (NASDAQ:LNTH) last released its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). The firm had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Lantheus’s revenue for the quarter was up .8% on a year-over-year basis. During the same quarter last year, the company posted $1.69 EPS. Analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Mary Anne Heino sold 53,107 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This trade represents a 10.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares of the company’s stock, valued at $11,445,207.20. The trade was a 8.07% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 63,109 shares of company stock worth $6,016,046. Corporate insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.